222 related articles for article (PubMed ID: 6431482)
1. Investigational trials of anticancer drugs: establishing safeguards for experimentation.
Chabner BA; Wittes R; Hoth D; Hubbard S
Public Health Rep; 1984; 99(4):355-60. PubMed ID: 6431482
[TBL] [Abstract][Full Text] [Related]
2. Promising new agents under development by the Division of Cancer Treatment, Diagnosis, and Centers of the National Cancer Institute.
Christian MC; Pluda JM; Ho PT; Arbuck SG; Murgo AJ; Sausville EA
Semin Oncol; 1997 Apr; 24(2):219-40. PubMed ID: 9129691
[TBL] [Abstract][Full Text] [Related]
3. The preclinical new drug research program of the National Cancer Institute.
Driscoll JS
Cancer Treat Rep; 1984 Jan; 68(1):63-76. PubMed ID: 6692438
[TBL] [Abstract][Full Text] [Related]
4. Anticancer Drug Development: The Way Forward.
Connors T
Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
[TBL] [Abstract][Full Text] [Related]
5. Can single-patient investigational new drug studies hurry slow trains to the fast track?
Chenoweth D
Drug Discov Today; 2006 Mar; 11(5-6):185-6. PubMed ID: 16580594
[TBL] [Abstract][Full Text] [Related]
6. The NCI All Ireland Cancer Conference.
Johnston PG; Daly PA; Liu E
Oncologist; 1999; 4(4):275-277. PubMed ID: 10545862
[TBL] [Abstract][Full Text] [Related]
7. [Present strategy for new drug development in the USA].
Shimada Y
Gan To Kagaku Ryoho; 1994 Oct; 21 Suppl 3():315-24. PubMed ID: 7986110
[TBL] [Abstract][Full Text] [Related]
8. Clinical development of anticancer agents--a National Cancer Institute perspective.
Marsoni S; Wittes R
Cancer Treat Rep; 1984 Jan; 68(1):77-85. PubMed ID: 6362870
[No Abstract] [Full Text] [Related]
9. Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents.
Dancey JE; Dobbin KK; Groshen S; Jessup JM; Hruszkewycz AH; Koehler M; Parchment R; Ratain MJ; Shankar LK; Stadler WM; True LD; Gravell A; Grever MR;
Clin Cancer Res; 2010 Mar; 16(6):1745-55. PubMed ID: 20215558
[TBL] [Abstract][Full Text] [Related]
10. Closing Remarks.
Reed E
Oncologist; 1996; 1(4):276-277. PubMed ID: 10388002
[TBL] [Abstract][Full Text] [Related]
11. Phase 0 clinical trials in oncology: a paradigm shift for early drug development?
Takimoto CH
Cancer Chemother Pharmacol; 2009 Mar; 63(4):703-9. PubMed ID: 18615251
[TBL] [Abstract][Full Text] [Related]
12. Developing new agents for the treatment of childhood cancer.
Kurmasheva R; Morton C; Houghton PJ
Curr Opin Investig Drugs; 2005 Dec; 6(12):1215-27. PubMed ID: 16372407
[TBL] [Abstract][Full Text] [Related]
13. NIH and NCI support for development of novel therapeutics in gynecologic cancer: a user's guide.
Minig L; Trimble EL; Birrer MJ; Kim KY; Takebe N; Abrams JS
Gynecol Oncol; 2010 Feb; 116(2):177-80. PubMed ID: 19889449
[TBL] [Abstract][Full Text] [Related]
14. Anticancer drug development at the US National Cancer Institute.
Takimoto CH
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S29-33. PubMed ID: 12819935
[TBL] [Abstract][Full Text] [Related]
15. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.
Greenwald P
J Cell Biochem Suppl; 1996; 25():29-36. PubMed ID: 9027595
[TBL] [Abstract][Full Text] [Related]
16. The role of the National Cancer Institute in drug development.
Doroshow J
Clin Adv Hematol Oncol; 2005 Apr; 3(4):257-8. PubMed ID: 16166997
[No Abstract] [Full Text] [Related]
17. Beware the Medical-Industrial Complex.
Stevens CW; Glatstein E
Oncologist; 1996; 1(4):IV-V. PubMed ID: 10388005
[TBL] [Abstract][Full Text] [Related]
18. Clinical trials: a recent emphasis in the prevention program of the National Cancer Institute.
DeWys WD; Greenwald P
Semin Oncol; 1983 Sep; 10(3):360-4. PubMed ID: 6665563
[No Abstract] [Full Text] [Related]
19. Anticancer metal compounds in NCI's tumor-screening database: putative mode of action.
Huang R; Wallqvist A; Covell DG
Biochem Pharmacol; 2005 Apr; 69(7):1009-39. PubMed ID: 15763539
[TBL] [Abstract][Full Text] [Related]
20. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
